Oncotarget · 2018 · 38 citations · 37 references
MedicineGeneticsMolecular BiologyEpigeneticsMolecular OncologyTranscriptomicsCancer EpigeneticsDna Methylation ProfilingEpigenetic Biomarker AnalysisEpigenetic Biomarker DiscoveryEpigenetic BiomarkersPediatric LeukemiasAcute Myeloid Leukemia BiologyCancer Epigenetic BiomarkersClinical Outcome MeasurementDna Methylation PatternsGenetic Prognostic MarkersGenome-wide Methylation AnalysisGenome-wide Methylation ProfilingMinimal Residual Disease Markers
// Jatinder K. Lamba 1 , Xueyuan Cao 2 , Susana C. Raimondi 3 , Roya Rafiee 1 , James R. Downing 3 , Lei Shi 2 , Tanja Gruber 4 , Raul C. Ribeiro 4 , Jeffrey E. Rubnitz 4 and Stanley B. Pounds 2 1 Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA 2 Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA 3 Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA 4 Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA Correspondence to: Jatinder K. Lamba, email: jlamba@cop.ufl.edu Keywords: AML; methylation; pediatrics; leukemia Received: February 16, 2018 Accepted: May 10, 2018 Published: June 01, 2018 ABSTRACT Acute myeloid leukemia (AML) may be an epigenetically-driven malignancy because it harbors fewer genomic mutations than other cancers. In recent studies of AML in adults, DNA methylation patterns associate with clinical risk groups and prognosis. However, thorough evaluations of methylation in pediatric AML have not been done. Therefore, we performed an integrated analysis (IA) of the methylome and transcriptome with clinical outcome in 151 pediatric patients from the multi-center AML02 clinical trial discovery cohort. Intriguingly, reduced methylation and increased expression of DNMT3B was associated with worse clinical outcomes (IA p ≤ 10 −5 ; q ≤ 0.002). In particular, greater DNMT3B expression associated with worse minimal residual disease (MRD; p < 10 −5 ; q = 0.01), a greater rate of relapse or resistant disease (RR) ( p = 0.00006; q = 0.06), and event-free survival (EFS; p = 0.00003; q = 0.04). Also, greater DNMT3B expression associated with greater genome-wide methylation burden (GWMB; R = 0.39; p = 10 −6 ) and greater GWMB associated with worse clinical outcomes (IA p < 10 −5 ). In an independent validation cohort of 132 similarly treated AAML0531 clinical trial patients, greater DNMT3B expression associated with greater GWMB, worse MRD, worse RR, and worse EFS (all p < 0.03); also, greater GWMB associated with worse MRD ( p = 0.004) and EFS ( p = 0.037). These results indicate that DNMT3B and GWMB may have a central role in the development and prognosis of pediatric AML.
37
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
María E. Figueroa, Sanne Lugthart, Yushan Li et al. · Cancer Cell · 2010 · 833 citations · Full text
Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi et al. · Journal of Clinical Oncology · 2014 · 472 citations · Full text
Medicine, Oncology, Pediatrics +17
Gene expression profiling of pediatric acute myelogenous leukemia
Mary Elizabeth Ross, Rami Mahfouz, Mihaela Onciu et al. · Blood · 2004 · 452 citations